Crewe Advisors’s ResMed RMD Stock Holding History

Crewe Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.46K	Buy	28 +9	+47%	+$1.86K	﹤0.01%	863
2026 Q1	$4.27K	Buy	19 +17	+850%	+$4.24K	﹤0.01%	805
2025 Q4	$482	Buy	+2	New	+$511	﹤0.01%	1045
2025 Q3	–	Sell	-2	Closed	-$516	–	1041
2025 Q2	$516	Buy	+2	New	+$477	﹤0.01%	645
2024 Q4	–	Sell	-62	Closed	-$15.1K	–	773
2024 Q3	$15.1K	Sell	62 -24	-28%	-$5.36K	﹤0.01%	434
2024 Q2	$16.5K	Buy	86 +24	+39%	+$4.87K	﹤0.01%	588
2024 Q1	$12.3K	Buy	+62	New	+$11.4K	﹤0.01%	592
2023 Q3	–	Sell	-11	Closed	-$2.4K	–	853
2023 Q2	$2.4K	Sell	11 -196	-95%	-$43.7K	﹤0.01%	521
2023 Q1	$45.3K	Sell	207 -125	-38%	-$27.1K	0.01%	317
2022 Q4	$69.1K	Sell	332 -67	-17%	-$14.7K	0.01%	269
2022 Q3	$87K	Buy	399 +71	+22%	+$16.2K	0.02%	241
2022 Q2	$69K	Buy	+328	New	+$69.8K	0.02%	257
2021 Q4	–	Sell	-9	Closed	-$2K	–	453
2021 Q3	$2K	Hold	9	–	–	﹤0.01%	362
2021 Q2	$2K	Hold	9	–	–	﹤0.01%	408
2021 Q1	$2K	Hold	9	–	–	﹤0.01%	416
2020 Q4	$2K	Hold	9	–	–	﹤0.01%	406
2020 Q3	$2K	Buy	+9	New	+$1.66K	﹤0.01%	524

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Crewe Advisors's RMD Position: Q2 2026 in Review

Crewe Advisors increased its ResMed (RMD) stake by 47% in Q2 2026, buying an estimated $1.86K and bringing the position to 28 shares worth $5.46K. The position accounts for ﹤0.01% of the portfolio, ranked #863.

Crewe Advisors first reported a position in RMD in Q3 2020 and has held it in 17 quarters since. The position peaked at $87K in Q3 2022. 890 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Crewe Advisors held 28 shares of ResMed worth $5.46K as of Q2 2026.
Crewe Advisors bought 9 ResMed shares in Q2 2026, an estimated $1.86K.
ResMed made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #863 holding.
Crewe Advisors first reported a position in ResMed in Q3 2020 and has held it in 17 quarters since.
Crewe Advisors's ResMed position peaked at $87K in Q3 2022.
890 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.